The rising incidence of cancer, developing infrastructure for cancer diagnosis, recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.
The consumables segment is expected to grow at the highest growth rate during the forecast period.
This is attributed primarily to their requirement in large numbers, cost-effectiveness, and ease of use.
The increasing number of reagent rental agreements is also one of the major factors to drive the growth of the consumables market globally.
The immunohistochemistry segment is estimated to register the highest CAGR during the forecast period.
This can primarily be attributed to the increasing prevalence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.Easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenarios for pathology diagnostic tests, increasing healthcare expenditure, and high-quality infrastructure for hospitals and clinical laboratories in this region are the major factors driving the growth of the tissue diagnostic market in North America.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1063949Key Market PlayersThe prominent players operating in the tissue diagnostic market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy).